Fecal Microbial Transplantation for Rheumatoid Arthritis Trial

Arthritis, Rheumatoid Clinical Trial

— FeMiTRA  

Official title:

Fecal Microbial Transplantation for Rheumatoid Arthritis Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05790356
• Other study ID #: FeMiTRA01
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 1, 2023
• Est. completion date: April 1, 2025

Study information

• Verified date: June 2023
• Source: Lawson Health Research Institute
• Contact: Lillian Barra, MD, MPH
• Phone: 519-646-6100
• Email: Lillian.Barra[@]sjhc.london.on.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial will investigate the effects of capsules containing stool from healthy donors, called fecal microbial transplant (FMT), in rheumatoid arthritis patients.

Description:

This is a randomized double-blind placebo-controlled proof-of-concept trial. A total of 30 RA patients will be asked to join the study. They will be randomized to receive capsular FMT + standard of care or placebo + standard of care. There will be four study visits in total: Baseline, FMT administration, 6- and 12-week follow-up visits. Follow-up visits will consist of assessment by a rheumatologist, completion of surveys, and collection of biologic samples.

Samples for the study are stool, urine and blood. Blood and fecal samples will be collected at baseline, 6 weeks and 12 weeks. Urine samples will be collected at baseline and 6 weeks.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: April 1, 2025
• Est. primary completion date: October 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18-years old or older

• RA diagnosis by ACR/EULAR criteria [26]

• Positive for the RA-associated antibodies, anti-citrullinated protein/peptide antibodies (ACPA) and/or rheumatoid factor (RF)

• Stable RA therapy > 6 months

• Patient in remission or low disease activity by DAS28

• Consents to study

Fecal Donor Inclusion Criteria:

• A healthy donor who has a normal body mass index (BMI of 18.5-30) and who satisfies the following criteria will be selected from a pool of donors available in the Infectious Diseases clinic at St. Joseph's Hospital supervised by Dr. Silverman and screened for all transmissible agents. at the Microbiology and Immunology lab at St. Joseph's Hospital under Dr. Silverman for the study and screened for transmissible agents.

Exclusion Criteria:

• Pregnant or breastfeeding

• Current or recent [in the last 60 days] exposure to high dose oral (>30 mg of prednisone daily or equivalent), IV corticosteroids, biologic therapies or JAKi.

• Patients who require inhaled steroids or local steroid injections are not excluded from the study

• Has a diagnosis of immunodeficiency (HIV, transplantation, or autoimmune disease other than RA requiring immunosuppressive therapies), or currently receiving systemic steroid therapy (>10 mg prednisone daily or equivalent)

• Received rituximab or other chemotherapeutic agent in the last 2 years.

• Expected to require any other form of systemic or localized anti-neoplastic therapy while on study

• Has a known history of a hematologic malignancy, primary brain tumor or sarcoma, or of another primary solid tumor, unless the patient has undergone potentially curative therapy with no evidence of that disease for five years. NOTE: This time requirement also does not apply to patients who underwent successful definitive resection of basal or squamous cell carcinoma of the skin, superficial bladder cancer, in situ cancers including cervical cancer, breast cancer, melanoma, or other in situ cancers.

• Ongoing use of antibiotics/anti-virals or previous use of antibiotics/anti-virals in the last 3 months prior to the FMT procedure

• Has an active infection requiring systemic therapy or requiring hospital admission in last 3 months.

• Presence of a chronic intestinal disease (e.g. Celiac disease, malabsorption, colonic tumor, IBD)

• Presence of absolute contra-indications to FMT administration

• Toxic megacolon

• Anaphylactic allergic reactions to food (e.g. shellfish, nuts, seafood, eggs)

• Has serious uncontrolled concomitant illnesses, such as: cardiovascular disease (uncontrolled congestive heart failure, hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmia), severe obstructive or restrictive pulmonary diseases, cirrhosis or ALT>100, renal disease with GFR<50 and uncontrolled psychiatric illness.

• Patient has received a live vaccine within 4 weeks prior to the first dose of treatment

• Insulin-dependent diabetes

• Previous bariatric surgery

• Chronic neutropenia (<0.5) Currently participating in another clinical trial

Fecal Donor Exclusion Criteria:

• Any underlying metabolic disease including; hypertension, hyperlipidemia, diabetes, insulin insensitivity, atherosclerosis

• A history of any gastrointestinal or liver disorders or cancers. Including but not limited to; gastroesophageal reflux, peptic ulcer disease, celiac disease, inflammatory bowel disease (Crohn's disease or ulcerative colitis), microscopic colitis, motility disorders (including gastroparesis and irritable bowel syndrome) diverticular disease

• Previous surgery to the intestine, liver or gallbladder (except remote appendectomy)

• History of any malignancy

• Use within 3 months of any antibiotics

• Hospitalization within 3 months

• Recent travel to a developing country (within 3 months).

• New Sexual Partner (within 3 months)

• Street drug use, family history of diabetes, early onset coronary disease or gastrointestinal or liver disease, colon cancer, familial malignancy

• Psychiatric history (major affective disorder, psychotic illness, ongoing use of any psychiatric medications)

• Any positive laboratory results for a transmissible pathogen

• Alcohol intake with a cut off value of <10g/d in women and <20g/d in men

• Currently participating in another clinical trial that may alter fecal composition.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Fecal Microbiota Transplantation

Intervention

Drug:
• Fecal Microbial transplant
Fecal microbial transplant will be investigated for its effect on gut bacterial composition in patients with rheumatoid arthritis.

Other:
• Placebo capsules
The placebo capsules will not contain FMT but will have the same appearance.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Lawson Health Research Institute	St. Joseph's Health Care London

References & Publications (31)

Al KF, Bisanz JE, Gloor GB, Reid G, Burton JP. Evaluation of sampling and storage procedures on preserving the community structure of stool microbiota: A simple at-home toilet-paper collection method. J Microbiol Methods. 2018 Jan;144:117-121. doi: 10.1016/j.mimet.2017.11.014. Epub 2017 Nov 16. — View Citation

Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005 Sep;52(9):2625-36. doi: 10.1002/art.21235. — View Citation

Barnabe C, Sun Y, Boire G, Hitchon CA, Haraoui B, Thorne JC, Tin D, van der Heijde D, Curtis JR, Jamal S, Pope JE, Keystone EC, Bartlett S, Bykerk VP; CATCH Investigators. Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH). PLoS One. 2015 Aug 24;10(8):e0135327. doi: 10.1371/journal.pone.0135327. eCollection 2015. — View Citation

Bombardier C, Hazlewood GS, Akhavan P, Schieir O, Dooley A, Haraoui B, Khraishi M, Leclercq SA, Legare J, Mosher DP, Pencharz J, Pope JE, Thomson J, Thorne C, Zummer M, Gardam MA, Askling J, Bykerk V; Canadian Rheumatology Association. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol. 2012 Aug;39(8):1583-602. doi: 10.3899/jrheum.120165. Epub 2012 Jun 15. — View Citation

Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, Khraishi M, Leclercq SA, Legare J, Mosher DP, Pencharz J, Pope JE, Thomson J, Thorne C, Zummer M, Bombardier C; Canadian Rheumatology Association. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012 Aug;39(8):1559-82. doi: 10.3899/jrheum.110207. Epub 2011 Sep 15. — View Citation

Chapman BC, Moore HB, Overbey DM, Morton AP, Harnke B, Gerich ME, Vogel JD. Fecal microbiota transplant in patients with Clostridium difficile infection: A systematic review. J Trauma Acute Care Surg. 2016 Oct;81(4):756-64. doi: 10.1097/TA.0000000000001195. — View Citation

Claytor JD, El-Nachef N. Fecal microbial transplant for inflammatory bowel disease. Curr Opin Clin Nutr Metab Care. 2020 Sep;23(5):355-360. doi: 10.1097/MCO.0000000000000676. — View Citation

Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, Hramiak I, Hegele R, Joy T, Meddings J, Urquhart B, Harvie R, McKenzie C, Summers K, Reid G, Burton JP, Silverman M. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. Am J Gastroenterol. 2020 Jul;115(7):1055-1065. doi: 10.14309/ajg.0000000000000661. — View Citation

Craven LJ, Nair Parvathy S, Tat-Ko J, Burton JP, Silverman MS. Extended Screening Costs Associated With Selecting Donors for Fecal Microbiota Transplantation for Treatment of Metabolic Syndrome-Associated Diseases. Open Forum Infect Dis. 2017 Nov 6;4(4):ofx243. doi: 10.1093/ofid/ofx243. eCollection 2017 Fall. — View Citation

Daisley BA, Chanyi RM, Abdur-Rashid K, Al KF, Gibbons S, Chmiel JA, Wilcox H, Reid G, Anderson A, Dewar M, Nair SM, Chin J, Burton JP. Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients. Nat Commun. 2020 Sep 24;11(1):4822. doi: 10.1038/s41467-020-18649-5. Erratum In: Nat Commun. 2020 Dec 9;11(1):6394. — View Citation

Deane KD, Holers VM. Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift. Arthritis Rheumatol. 2021 Feb;73(2):181-193. doi: 10.1002/art.41417. Epub 2020 Dec 8. — View Citation

Gwinnutt JM, Wieczorek M, Balanescu A, Bischoff-Ferrari HA, Boonen A, Cavalli G, de Souza S, de Thurah A, Dorner TE, Moe RH, Putrik P, Rodriguez-Carrio J, Silva-Fernandez L, Stamm T, Walker-Bone K, Welling J, Zlatkovic-Svenda MI, Guillemin F, Verstappen SMM. 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2023 Jan;82(1):48-56. doi: 10.1136/annrheumdis-2021-222020. Epub 2022 Mar 8. — View Citation

Holers VM, Demoruelle MK, Kuhn KA, Buckner JH, Robinson WH, Okamoto Y, Norris JM, Deane KD. Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction. Nat Rev Rheumatol. 2018 Sep;14(9):542-557. doi: 10.1038/s41584-018-0070-0. — View Citation

Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, Chang HJ, Coward S, Goodman KJ, Xu H, Madsen K, Mason A, Wong GK, Jovel J, Patterson J, Louie T. Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 2017 Nov 28;318(20):1985-1993. doi: 10.1001/jama.2017.17077. — View Citation

Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012 Dec;51 Suppl 6:vi5-9. doi: 10.1093/rheumatology/kes279. — View Citation

Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, Moore T, Wu G. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology. 2015 Jul;149(1):223-37. doi: 10.1053/j.gastro.2015.05.008. Epub 2015 May 15. — View Citation

Loyola-Sanchez A, Hazlewood G, Crowshoe L, Linkert T, Hull PM, Marshall D, Barnabe C. Qualitative Study of Treatment Preferences for Rheumatoid Arthritis and Pharmacotherapy Acceptance: Indigenous Patient Perspectives. Arthritis Care Res (Hoboken). 2020 Apr;72(4):544-552. doi: 10.1002/acr.23869. — View Citation

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9. doi: 10.1007/BF00280883. — View Citation

Meyers S, Shih J, Neher JO, Safranek S. Clinical Inquiries: How effective and safe is fecal microbial transplant in preventing C difficile recurrence? J Fam Pract. 2018 Jun;67(6):386-388. — View Citation

Mohammed AT, Khattab M, Ahmed AM, Turk T, Sakr N, M Khalil A, Abdelhalim M, Sawaf B, Hirayama K, Huy NT. The therapeutic effect of probiotics on rheumatoid arthritis: a systematic review and meta-analysis of randomized control trials. Clin Rheumatol. 2017 Dec;36(12):2697-2707. doi: 10.1007/s10067-017-3814-3. Epub 2017 Sep 15. — View Citation

Munro S, Spooner L, Milbers K, Hudson M, Koehn C, Harrison M. Perspectives of patients, first-degree relatives and rheumatologists on preventive treatments for rheumatoid arthritis: a qualitative analysis. BMC Rheumatol. 2018 Jul 5;2:18. doi: 10.1186/s41927-018-0026-7. eCollection 2018. — View Citation

Neill J, Belan I, Ried K. Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: a systematic review. J Adv Nurs. 2006 Dec;56(6):617-35. doi: 10.1111/j.1365-2648.2006.04054.x. Erratum In: J Adv Nurs. 2007 Jan;57(2):225. — View Citation

Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, Rostron T, Cerundolo V, Pamer EG, Abramson SB, Huttenhower C, Littman DR. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife. 2013 Nov 5;2:e01202. doi: 10.7554/eLife.01202. — View Citation

Skoldstam L, Hagfors L, Johansson G. An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Ann Rheum Dis. 2003 Mar;62(3):208-14. doi: 10.1136/ard.62.3.208. — View Citation

Sun D, Li W, Li S, Cen Y, Xu Q, Li Y, Sun Y, Qi Y, Lin Y, Yang T, Xu P, Lu Q. Fecal Microbiota Transplantation as a Novel Therapy for Ulcerative Colitis: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2016 Jun;95(23):e3765. doi: 10.1097/MD.0000000000003765. — View Citation

Svard A, Roos Ljungberg K, Brink M, Martinsson K, Sjowall C, Rantapaa Dahlqvist S, Kastbom A. Secretory antibodies to citrullinated peptides in plasma and saliva from rheumatoid arthritis patients and their unaffected first-degree relatives. Clin Exp Immunol. 2020 Feb;199(2):143-149. doi: 10.1111/cei.13381. Epub 2019 Oct 22. — View Citation

Taylor PC, Ancuta C, Nagy O, de la Vega MC, Gordeev A, Jankova R, Kalyoncu U, Lagunes-Galindo I, Morovic-Vergles J, de Souza MPGUES, Rojkovich B, Sidiropoulos P, Kawakami A. Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study. Patient Prefer Adherence. 2021 Feb 17;15:359-373. doi: 10.2147/PPA.S289692. eCollection 2021. — View Citation

Vehreschild MJ, Cornely OA. Fecal Microbiota Transfer 2.0. J Infect Dis. 2016 Jul 15;214(2):169-70. doi: 10.1093/infdis/jiv768. Epub 2016 Feb 8. No abstract available. — View Citation

Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, Yan F, Cao H, Wang B. Systematic Review: Adverse Events of Fecal Microbiota Transplantation. PLoS One. 2016 Aug 16;11(8):e0161174. doi: 10.1371/journal.pone.0161174. eCollection 2016. — View Citation

Wilson AS, Koller KR, Ramaboli MC, Nesengani LT, Ocvirk S, Chen C, Flanagan CA, Sapp FR, Merritt ZT, Bhatti F, Thomas TK, O'Keefe SJD. Diet and the Human Gut Microbiome: An International Review. Dig Dis Sci. 2020 Mar;65(3):723-740. doi: 10.1007/s10620-020-06112-w. — View Citation

Zaiss MM, Joyce Wu HJ, Mauro D, Schett G, Ciccia F. The gut-joint axis in rheumatoid arthritis. Nat Rev Rheumatol. 2021 Apr;17(4):224-237. doi: 10.1038/s41584-021-00585-3. Epub 2021 Mar 5. — View Citation

* Note: There are 31 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pain Visual Analog Scale	Change in pain will be measured using a visual analog scale.	Baseline, 6 weeks and 12 weeks
Other	Fatigue	Change in fatigue will be measured with a visual analog scale.	Baseline, 6 weeks and 12 weeks
Other	Sleep	Change in sleep will be measured with a visual analog scale.	Baseline, 6 weeks and 12 weeks
Other	Change in RA disease activity	RA disease activity will be measured using the disease activity score-28 (DAS28).	Baseline, 6 weeks and 12 weeks
Other	Change in RA disease activity	RA disease activity will be measured using the health assessment questionnaire (HAQ).	Baseline, 6 weeks and 12 weeks
Other	Change in RA disease activity	RA disease activity will be measured using the clinical disease activity index (CDAI).	Baseline, 6 weeks and 12 weeks
Other	Insulin Resistance	Fasting glucose and insulin will be measured from a blood sample to calculate the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR).	Baseline, 6 weeks and 12 weeks
Other	Blood Pressure	Systolic and Diastolic blood pressure is part of the standard of care and will be measured at each study visit.	Baseline, 6 weeks and 12 weeks
Other	Body Mass Index	Body mass index is part of the standard of care and will be measured at each study visit.	Baseline, 6 weeks and 12 weeks
Other	Patient Acceptability of FMT	Participants will complete an acceptability of therapy survey for FMT. The survey asks them questions about how well the FMT process was explained to them, and how they feel about it. The participant is asked to select one answer per question ranging from :strongly agree" to "strongly disagree"	Baseline, 6 weeks and 12 weeks
Other	Tolerability of DMARD Therapy	Participants will complete a survey on tolerability of DMARD therapy.	Baseline, 6 weeks and 12 weeks
Primary	Change in Intestinal Permeability	A blood sample will be collected for bacterial DNA analysis.	Baseline and 6 weeks
Primary	Change in Intestinal Permeability	A urine sample will be collected to measure the lactulose to mannitol ratio.	Baseline and 6 weeks
Primary	Change in RA-associated autoantibodies	A blood sample will be collected to measure RA-associated autoantibodies.	Baseline, 6 weeks and 12 weeks
Primary	Adverse Events	Adverse events will be evaluated at every study visit. Participants will also be instructed to contact study staff by phone if they experience an adverse event in between study visits.	Baseline
Primary	Adverse Events	Adverse events will be evaluated at every study visit. Participants will also be instructed to contact study staff by phone if they experience an adverse event in between study visits.	FMT treatment visit
Primary	Adverse Events	Adverse events will be evaluated at every study visit. Participants will also be instructed to contact study staff by phone if they experience an adverse event in between study visits.	6 weeks post-treatment
Primary	Adverse Events	Adverse events will be evaluated at every study visit. Participants will also be instructed to contact study staff by phone if they experience an adverse event in between study visits.	12 weeks post-treatment
Secondary	Change in Fecal Microbial Composition	Stool samples will be collected to determine fecal microbial composition using 16S-RNA sequencing.	Baseline, 6 weeks and 12 weeks
Secondary	Change in C-Reactive Protein	Blood sample will be collected to measure CRP levels.	Baseline, 6 weeks and 12 weeks.